NAC (N-Acetylcysteine): Glutathione Precursor, Mucolytic, And Mental Health

NAC is the rare supplement that started as a hospital drug, which means the evidence for it is unusually good and unusually specific about where it does nothing.

In this post, we will discuss how NAC actually raises glutathione, why the cystine-glutamate antiporter explains almost everything it does in the brain, which psychiatric indications have real data and which have failed replication, the respiratory and biofilm uses, the regulatory fight over its supplement status, and the genetics that decide whether you tolerate it at all.

---

What Is NAC

N-Acetylcysteine (NAC) is the acetylated form of the amino acid cysteine, and the acetyl group on the nitrogen is the entire reason it works as an oral agent. R

Free cysteine is unstable in solution, oxidizes readily to cystine, and is poorly tolerated at the doses that would be needed to shift glutathione. R

NAC was approved as a drug decades before anyone sold it as a supplement, first as an inhaled mucolytic and then as the antidote for acetaminophen poisoning. R

That drug history is why the literature is far better than for most supplements, and it is also the reason for the regulatory mess covered further down.

How NAC Raises Glutathione

Cysteine is the rate-limiting substrate for glutathione synthesis, so anything that reliably raises intracellular cysteine raises glutathione. R

NAC is deacetylated to cysteine, which then combines with glutamate and glycine in two ATP-dependent steps to form glutathione. R

The important and rarely mentioned detail is that oral NAC has low bioavailability, on the order of 10%, because it is extensively deacetylated before it ever reaches systemic circulation. R

The deacetylation happens largely in the intestinal mucosa rather than the liver, which is why an isolated perfused liver barely metabolizes NAC on a single pass. R

Red blood cells also take up and deacetylate NAC, adding another compartment that consumes the dose before it does anything useful. R

Peak plasma concentrations arrive within one to three hours, and the pharmacologically active species being measured is cysteine, not NAC itself. R

This is the honest reason clinical doses are 1,200 mg to 2,400 mg rather than the 600 mg that would be plenty if absorption were efficient. R

The Cystine-Glutamate Antiporter

This is the mechanism that explains why a glutathione precursor has any business in psychiatry at all.

System xc- is an antiporter sitting mostly on astrocytes, built from the xCT subunit encoded by SLC7A11 paired with 4F2hc. R

It imports one cystine and exports one glutamate, in a strict one-to-one exchange. R

Raising extracellular cystine therefore does two things at once: it feeds intracellular glutathione synthesis, and it increases the glutamate sitting in the extrasynaptic space. R

That extrasynaptic glutamate stimulates inhibitory group II metabotropic glutamate receptors on presynaptic terminals, which then dial DOWN synaptic glutamate release. R

The counterintuitive result is that giving a compound which increases total glutamate ends up restraining pathological glutamate signaling, which is the opposite of what most people assume when they hear "glutamate."

If glutamate and neuroinflammation is a topic you are already working on, this is the specific lever NAC pulls, and it is why NAC shows up in compulsive and addictive conditions rather than in anxiety generally.

In cocaine use disorder, magnetic resonance spectroscopy showed NAC normalizing elevated glutamate levels in a randomized crossover design, which is direct human evidence for the mechanism rather than an inference from rodents. R

Repeated drug exposure downregulates both system xc- and the glial glutamate transporter GLT-1 in the nucleus accumbens, which is the deficit NAC is thought to correct. R

Mental Health Evidence, Graded Honestly

The psychiatric literature on NAC is genuinely mixed, and the honest summary is that it is strong in a narrow band of conditions and unimpressive in the ones it gets recommended for most.

Trichotillomania And Skin Picking

The strongest single result is Grant's 2009 double-blind trial in adults with trichotillomania, where 1,200 mg to 2,400 mg produced a large and statistically significant reduction in hair pulling. R

Then a similarly designed pediatric trial in 39 children and adolescents found no benefit at all. R

There is a big MAYBE here, and the age split is the most interesting unexplained part of the NAC literature rather than something to wave away.

The practical read is that the adult data is worth acting on and the pediatric data is not, which is an unsatisfying place to land but is what the trials actually say.

OCD

A 2024 systematic review and meta-analysis of six randomized trials in 195 adults examined NAC as an SSRI augmentation strategy for moderate to severe OCD. R

Individual trials disagree, with some multicenter randomized data showing benefit on Yale-Brown Obsessive-Compulsive Scale scores and others showing nothing. R

Given that 40% to 60% of OCD patients do not respond adequately to an SSRI alone, NAC is a low-risk augmentation attempt rather than a primary treatment. R

Bipolar Depression

Berk's 2008 trial found meaningful improvement in depressive symptoms and function with 2 g per day as an adjunct. R

The maintenance trial that followed, in patients who had already completed eight weeks of open-label NAC, found no significant between-group difference in recurrence or symptomatic outcomes. R

A larger three-arm 16-week randomized trial in 2019, testing NAC alone and NAC combined with mitochondrial agents against placebo, also failed to separate from placebo. R

Anyone recommending NAC for bipolar depression on the strength of the 2008 trial without mentioning the two later negative trials is not reading the literature honestly.

Schizophrenia

The 2008 randomized trial of NAC as a glutathione precursor in schizophrenia found improvement in negative symptoms, which matter because they respond poorly to antipsychotics. R

Pooled analyses have reported large effect sizes for negative symptoms after 24 weeks of treatment. R

A trial specifically in clozapine-resistant patients found no improvement in negative symptoms, cognition, or quality of life across a full year. R

There is a plausible reading in which NAC helps the patients who still have redox reserve to recruit and does nothing for the most treatment-refractory end of the spectrum. R

Substance Use

A meta-analysis of randomized controlled trials found NAC reduced craving ratings, with no significant difference between substance classes including alcohol, cocaine, nicotine, and amphetamine. R

The cleanest single trial is the 8-week randomized study in 116 cannabis-dependent adolescents given 1,200 mg twice daily alongside contingency management. R

Craving reduction is a real but modest effect, and NAC is an adjunct to behavioral treatment rather than a replacement for it.

Mucolytic And Respiratory Use

NAC's free thiol group reduces the disulfide bonds cross-linking mucin glycoproteins, which lowers mucus viscosity directly through chemistry rather than through any receptor. R

The COPD literature is the best illustration of why dose and population matter.

The BRONCUS trial published in the Lancet in 2005 gave 600 mg daily and concluded NAC did not prevent lung function decline or exacerbations. R

The PANTHEON trial gave 600 mg TWICE daily to Chinese patients with moderate to severe COPD and found a significant reduction in exacerbations. R70286-8/fulltext)

A separate randomized trial of high-dose oral NAC found no improvement in respiratory health status, so the picture is not uniformly positive even at the higher dose. R

Meta-analysis of chronic bronchitis and COPD populations supports a modest reduction in exacerbations, with the effect concentrated in patients not already on inhaled corticosteroids. R

For influenza, the De Flora trial remains the most quoted result, and it is genuinely interesting: 262 subjects took 600 mg twice daily for six months, and while seroconversion rates were identical between groups, only 25% of infected subjects on NAC developed symptoms versus 79% on placebo. R

That is a symptom-modifying effect, not an antiviral one, and NAC does not have universal inhibitory activity against influenza A viruses in vitro. R

COVID-era meta-analysis reported reduced severity and mortality, though the trial quality in that literature is uneven enough that it should be held loosely. R

The mechanistic rationale for post-viral use rests on glutathione depletion and neutrophil-driven oxidative damage rather than direct viral inhibition. R

Oxidative stress is a measured, shared feature of both ME/CFS and long COVID, which is the honest basis for trying NAC in post-viral illness. R

Readers working through post-viral recovery should treat NAC as one input inside the broader long COVID protocol rather than as a standalone answer.

Jacob's hypothesis is that a large part of chronic post-viral illness runs through Micro-Sepsis (MSS) and Transient Capillary Leak Syndrome (TCLS), both terms he coined, where endothelial and glycocalyx damage keeps a low-grade inflammatory loop running long after the acute infection clears.

That framing is his own and is not consensus medicine, and the full cascade is worked out in the Junction Dysfunction guide rather than here.

NAC fits that model as substrate support for a depleted antioxidant system, not as a treatment for the underlying junction damage, which is covered in rebuilding the glycocalyx.

Biofilm Disruption

This is the use that functional medicine leans on most heavily and that mainstream summaries of NAC skip entirely.

NAC disrupts established biofilms in a concentration-dependent way, and at 10 mg/mL it disrupted them completely in vitro. R

It also suppressed extracellular polysaccharide production by Pseudomonas aeruginosa by roughly 28% to 45% depending on concentration. R

Against Staphylococcus aureus and Pseudomonas biofilms on prosthetic materials, NAC disaggregated biofilm within three hours, with the effect differing by surface material. R

Combination treatments containing 30 mM NAC produced at least 90% biofilm disruption across MRSA and MSSA strains. R

The critical caveat is that these are in vitro concentrations achieved by bathing a biofilm directly, and oral dosing does not reliably reproduce them at a distant site.

Treat NAC as one agent in a stack rather than a solution, and read the biofilm and biofilm protocol posts for how the pieces fit together.

Acetaminophen Overdose

Acetaminophen is normally cleared by sulfation and glucuronidation, with a small fraction going through CYP2E1 to the reactive metabolite N-Acetyl-p-Benzoquinone Imine (NAPQI). R

At therapeutic doses NAPQI is immediately conjugated by glutathione and excreted harmlessly through the Phase II conjugation pathways. R

In overdose, sulfation and glucuronidation saturate, more drug shunts through CYP2E1, and hepatic glutathione is consumed faster than it can be resynthesized. R

Once glutathione is depleted, NAPQI binds covalently to mitochondrial proteins, and it is that adduct formation plus the resulting oxidant stress, not the drug itself, that kills hepatocytes. R

NAC works by restoring the glutathione supply so NAPQI is neutralized before it can form adducts, which is why timing dominates outcome. R

The Rumack-Matthew nomogram plots serum acetaminophen against hours since ingestion to decide who needs treatment, and it is only valid for measurements taken between 4 and 24 hours post-ingestion. R

This is emergency medicine, not a supplement protocol.

Suspected overdose means the emergency department, and nothing in this section should be read as a reason to manage it at home.

PCOS And Insulin Sensitivity

NAC has been studied in polycystic ovary syndrome on the strength of its antioxidant and insulin-sensitizing effects. R

Meta-analysis found NAC significantly reduced fasting blood glucose compared with placebo or metformin. R

It has also been associated with increased progesterone and endometrial thickness relative to comparators. R

For ovulation specifically the picture is worse, and a head-to-head trial in clomiphene-resistant PCOS reported an ovulation rate of 51.6% with metformin versus 6.7% with NAC. R

The reasonable conclusion is that NAC is a metabolic adjunct in PCOS and not an ovulation induction agent. R

The Honest Counter-Case

NAC is a reductant, and more reducing capacity is not automatically better.

Exercise adaptation is the clearest example, because the reactive oxygen species generated during training are the SIGNAL that drives mitochondrial biogenesis rather than damage to be suppressed. R

Ristow's PNAS trial found that antioxidant supplementation prevented the improvement in insulin sensitivity that exercise otherwise produced, in both untrained and pretrained subjects. R

A separate randomized trial found vitamin C and E supplementation blunted training-induced expression of genes tied to mitochondrial biogenesis. R

The thiol-specific literature suggests the same concern applies to NAC around training, which is a practical argument for dosing it away from workouts rather than abandoning either. R

The deeper point is that reductive stress is a real state and not merely the absence of oxidative stress.

Pushing thiols hard in someone who is not actually depleted is not a neutral act, and the better strategy in most chronic illness is inducing endogenous capacity through NRF2 rather than brute-force loading, which is what the sulforaphane data supports.

The FDA Supplement Fight

In 2020 and 2021 the FDA took the position that NAC is excluded from the definition of a dietary supplement, because it was approved as a drug before being marketed as a supplement and no regulation authorizing supplement use had been issued.

That reading follows the drug preclusion clause of the Federal Food, Drug, and Cosmetic Act, and it triggered warning letters and product delistings by major retailers.

On August 1, 2022 the FDA issued final guidance stating it intends to exercise enforcement discretion for NAC products that would otherwise be lawfully marketed supplements.

Enforcement discretion is not the same as legal status, and the FDA stated it will hold that position until it either completes rulemaking or denies the citizen petition requesting it.

The practical effect is that NAC is widely available again, on a policy that the agency can withdraw without changing any law.

Dosage And Safety

Doses used in the trials above cluster in a fairly narrow band despite the range of indications.

• N-acetylcysteine for psychiatric indications: 1,200 mg to 2,400 mg per day, usually split into two doses, with trials running 8 to 24 weeks before judging response. R
• N-acetylcysteine for respiratory use: 600 mg twice daily, which is the dose that separated from placebo where 600 mg once daily did not. R70286-8/fulltext)
• Glycine alongside NAC, because glycine is the other consumable substrate for glutathione synthesis and is frequently the co-limiting one. R

Gastrointestinal upset is the most common complaint, and much of it comes from the sulfurous smell and taste rather than from any systemic effect. R

Inhaled NAC can provoke bronchospasm in asthma, and oral dosing is the better route in anyone with reactive airways. R

The caveat that matters most for this audience is sulfur intolerance.

People with impaired sulfur handling, including those with Cystathionine Beta-Synthase (CBS) variants or significant mast cell involvement, often feel worse on NAC rather than better. R

If NAC reliably produces flushing, headache, or symptom flares, that is information about sulfur metabolism worth investigating rather than a dose to push through, and the histamine and MCAS picture frequently overlaps.

Anyone on anticoagulants or heading into surgery should raise NAC with their prescriber, since older reports suggest platelet effects even though clinical bleeding evidence with oral dosing is thin. R

Testing

Testing here is about confirming that oxidative stress and glutathione depletion are actually present, rather than assuming them.

Redox And Oxidative Stress Markers

I use the Oxidative Stress Analysis (Genova Diagnostics) to look at glutathione status alongside lipid peroxidation rather than reading a glutathione number in isolation.

The DNA Oxidative Damage Assay (Doctor's Data) measures 8-hydroxy-2-deoxyguanosine, which reflects oxidative damage that has already reached DNA.

The Cellular Zoomer (Vibrant Wellness) covers organic acids, mitochondrial function, and oxidative stress markers together, which is the better first pass when the picture is unclear.

Organic Acids

The Organic Acids Test (Mosaic Diagnostics) includes pyroglutamate, which rises when glutathione synthesis is running short of cysteine and is one of the few functional readouts of the exact deficit NAC corrects.

Liver And Metabolic

The Hepatic Function Panel (Quest Diagnostics) covers AST, ALT, GGT, ALP, and bilirubin, and GGT specifically tracks glutathione turnover rather than just hepatocyte injury.

The Comprehensive Metabolic Panel (Quest Diagnostics) is the baseline to pair with it.

For a fuller detox picture the Hepatic Detox Profile (Doctor's Data) assesses Phase I and Phase II capacity directly.

Sulfur And Methylation

The Homocysteine test matters because homocysteine sits directly upstream of cysteine via transsulfuration, and an elevated value can indicate the pathway feeding your own cysteine is blocked. R

The Methylation Genetics panel covers the variants that determine how well that pathway runs, and the methylation guide explains why it matters here.

Toxic Burden

Where mold or metals are the suspected driver of depletion, the Mycotoxins Profile (RealTime Labs) and the Toxin Zoomer (Vibrant Wellness) identify what is consuming the glutathione in the first place.

Chasing glutathione support without removing the exposure driving the depletion is the most common way this work fails, which the mold illness protocol covers in depth.

Mechanisms Of Action

Simple:

• NAC gives your cells the one raw material they run out of first when making glutathione.
• It breaks the chemical bonds that make mucus thick and sticky.
• It quietly turns down overactive glutamate signaling in the brain, which is why it helps compulsive and addictive behaviors more than mood itself.
• It pries apart the protective slime that bacteria build around themselves.

Advanced:

• Glutathione resynthesis. NAC is deacetylated to cysteine, which glutamate-cysteine ligase joins to glutamate and glutathione synthetase then joins to glycine, in the two ATP-dependent steps that constitute de novo glutathione synthesis. R
• Mucolysis by disulfide reduction. The free sulfhydryl group reduces disulfide cross-links between mucin glycoprotein subunits, lowering viscosity through direct chemical reduction with no receptor involvement. R
• System xc- exchange. Increased extracellular cystine drives the xCT/4F2hc antiporter, exporting glutamate into the extrasynaptic space where it activates inhibitory group II mGluRs and reduces synaptic glutamate release in the nucleus accumbens and prefrontal cortex. R
• Transporter restoration. Chronic drug exposure downregulates both system xc- and GLT-1, and NAC appears to restore glutamate homeostasis by acting on that specific deficit rather than by general antioxidant action. R
• NAPQI conjugation. In acetaminophen toxicity, restored glutathione conjugates NAPQI before it can form covalent adducts with mitochondrial proteins, which is the step that determines whether hepatocytes survive. R
• Biofilm matrix disruption. NAC reduces extracellular polysaccharide production and disaggregates the established matrix, in a concentration-dependent manner reaching complete disruption in vitro. R

Genetics

SLC7A11

SLC7A11 encodes xCT, the transporter subunit that performs the actual cystine-for-glutamate exchange NAC depends on. R

Expression of this transporter is downregulated in schizophrenia, which is the most direct genetic argument for why NAC would help that population specifically. R

CBS

Cystathionine Beta-Synthase (CBS) commits homocysteine into the transsulfuration pathway that produces your own cysteine. R

Transsulfuration activity can sustain the cellular cysteine pool when extracellular cysteine is limited, which means CBS function partly determines how much you depend on dietary or supplemental cysteine at all. R

Variants here are the most common reason someone in this audience reacts badly to sulfur donors, and homocysteine is the marker that makes the pathway visible.

GCLC And GCLM

Glutamate-Cysteine Ligase is the rate-limiting enzyme of glutathione synthesis, built from a catalytic subunit (GCLC) and a modifier subunit (GCLM). R

The GCLC -129T/C and GCLM -588C/T promoter polymorphisms sit in antioxidant response elements and change transcription of the enzyme itself, so they set the ceiling on how much glutathione you can build from any amount of cysteine. R

GSTM1 And GSTT1

Glutathione S-Transferase Mu 1 (GSTM1) and Glutathione S-Transferase Theta 1 (GSTT1) are deleted entirely in a large fraction of the population, producing a true null genotype rather than a reduced-function variant. R

Null carriers conjugate certain electrophiles less efficiently, which raises the value of keeping glutathione supply adequate. R

GSTP1 Ile105Val (rs1695)

Glutathione S-Transferase Pi 1 (GSTP1) handles conjugation in tissues where GSTM1 and GSTT1 are less expressed, including brain and lung. R

The Val allele at rs1695 alters substrate specificity and catalytic efficiency rather than abolishing function. R

SOD2 Ala16Val (rs4880)

Superoxide Dismutase 2 (SOD2) is the mitochondrial enzyme converting superoxide to hydrogen peroxide, upstream of everything glutathione does. R

The rs4880 variant changes the mitochondrial targeting sequence and therefore how efficiently the enzyme is imported into mitochondria, which shifts baseline oxidative load. R

GPX1 Pro198Leu (rs1050450)

Glutathione Peroxidase 1 (GPX1) is the enzyme that actually spends glutathione to reduce peroxides, and it requires selenium as selenocysteine at its active site. R

The Leu allele at rs1050450 is associated with lower enzyme activity and reduced responsiveness to selenium supplementation. R

Supplying more glutathione substrate accomplishes little if the enzyme meant to use it is both low-activity and selenium-deficient, which is why these three posts belong together.

More Research

• Alpha-lipoic acid. Alpha-lipoic acid regenerates oxidized glutathione rather than supplying substrate, which makes it complementary to NAC rather than redundant with it, and the two are frequently stacked for that reason.
• Early psychosis imaging. NAC add-on treatment improved fornix white matter integrity in a double-blind randomized trial in early psychosis, which is a structural readout rather than a symptom scale and is one of the more interesting signals in the literature. R
• Mast cell overlap. Sulfur intolerance and mast cell activation travel together often enough that a bad NAC reaction is worth investigating as a mast cell question rather than a dosing one, and the hypoxia connection is developed further in mitochondria and mast cells.
• Mercury and metals. Glutathione conjugation is a primary route for mercury handling, and mobilizing metals without adequate conjugation capacity in place is how people make themselves worse with an otherwise reasonable protocol.
• Mycotoxins. Ongoing mold exposure consumes glutathione faster than any oral precursor replaces it, which is why the mycotoxin picture has to be addressed before judging whether NAC is working.
• NRF2 induction. NRF2 activation raises GCLC and GCLM transcription, meaning it increases the machine while NAC only increases the fuel, and the two approaches answer different bottlenecks.
• Systemic inflammation. NAC's suppression of NF-kB signaling is the mechanism behind its cytokine effects, which places it in the same conversation as systemic and long-term inflammation rather than purely in antioxidant terms.
• Taurine. Taurine is the other major endpoint of the transsulfuration pathway, so sulfur amino acid status is better read as a whole picture than as any single marker.
• Testing. For readers tracking these markers across repeated panels rather than as a single snapshot, the Health Hub inside Pro membership is built for exactly that kind of longitudinal comparison.